Hetero Biopharma announce collaboration with RDIF as a manufacturing partner for producing SPUTNIK V vaccine in india.

Hetero, through its biologics arm Hetero Biopharma has been roped in as the manufacturing partner by the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), for producing Sputnik V the world's first registered vaccine against the novel coronavirus infection in India.

As per the agreement, Hetero Biopharma will be manufacturing over 100 million doses of the Sputnik V vaccine per year.


Editor’s Note: . Please make sure that you are subscribed to the TyroPharma Newsletter (*to Activate Subscription Verify Link in your E-Mail inbox*) to be notified of all of the latest & Upcoming Vacancies. Follow us on social media Facebook, Twitter, LinkedIn, WhatsApp, Telegram

Post a Comment